INB 100
Alternative Names: DeltEx Allo - IN8bio; INB-100Latest Information Update: 28 Mar 2025
At a glance
- Originator IN8bio
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Leukaemia(Second-line therapy or greater) in USA (Parenteral, Infusion)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Second-line therapy or greater) in USA (Parenteral, Infusion)
- 13 Mar 2025 Phase-I development is ongoing in Leukaemia and Myelodysplastic-syndromes (Second-line therapy or greater) in USA (Parenteral, Infusion)